S&P 500
5,940.46
-0.4%
-23.14
DJI
42,677.24
-0.3%
-114.83
NASDAQ
$19,142.71
-0.4%
-$72.75
Bitcoin
106,318.00
+1.1%
+1,110.85
AAPL
$206.73
-1.0%
-$2.05
AMZN
$204.08
-1.0%
-$2.08
GOOG
$165.14
-1.6%
-$2.73
META
$636.43
-0.6%
-$4.00
MSFT
$457.90
-0.2%
-$0.97
NVDA
$134.22
-1.0%
-$1.34
TSLA
$343.52
+0.4%
+$1.43
Checkpoint Therapeutics (NASDAQ: CKPT)
$4.16
(0.0%)
$0.00
Price as of May 20, 2025, 3:32 p.m. ET
Checkpoint Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Checkpoint Therapeutics Company Info
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.
News & Analysis
Featured Article
Why Checkpoint Therapeutics Stock Is Heating Up Today
Based on its latest clinical trial data, this small-cap biotech could have a best-in-class treatment for advanced skin cancer on the way.
George Budwell | Jan 25, 2022
Featured Article
Why Checkpoint Therapeutics Skyrocketed Today
One analyst becomes a fervent believer in the company's stock.
Eric Volkman | Jun 9, 2021
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.